Treatment of advanced Parkinson's disease in the United States: a cost-utility model
Groenendaal H, Tarrants ML, Armand C

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2165/11538520-000000000-00000

Indexing Status
Subject indexing assigned by NLM

MeSH
Antiparkinson Agents /administration & dosage /economics /therapeutic use; Carbidopa /economics /therapeutic use; Catechols /economics /therapeutic use; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans /economics /therapeutic use; Levodopa /economics /therapeutic use; Markov Chains; Models, Economic; Nitriles /economics /therapeutic use; Parkinson Disease /drug therapy /economics /physiopathology; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States

AccessionNumber
22010001717

Date bibliographic record published
22/12/2010